Tuesday, November 27, 2007 9:15:45 AM
Monday November 26, 1:06 pm ET
Maxygen Inc. and drugmaker Roche will end development of the hepatitis infection drug MAXY-alpha.
Roche in September had placed a hold on the program, which the companies had been developing since 2003.
Roche, which fully funded the MAXY-alpha program, had started a Phase Ia clinical trial in New Zealand at the end of 2006.
Redwood City-based Maxygen (NASDAQ: MAXY) expected no milestone payments in 2007 or 2008, the company said.
"While we are disappointed, we recognized and had advised earlier that termination of the program was one of the likely possibilities," said Maxygen CEO Russell Howard.
MAXY-alpha was designed to treat infections related to hepatitis C, the leading cause of liver cancer cases worldwide, and hepatitis B.
Published November 26, 2007 by San Francisco Business Times
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • Oct 1, 2024 7:00 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM